Merck, Inc.

DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer.

The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates.

Long-term follow-up of the KEYNOTE-671 trial demonstrates that perioperative pembrolizumab plus chemotherapy continues to improve event-free survival (EFS) and overall survival (OS).

The Phase III LEAP-001 trial evaluated lenvatinib plus pembrolizumab versus chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer.

Lupin secured tentative FDA approval for its generic version of Raltegravir 600mg tablets, a treatment for HIV-1 infection.

A phase II study (OLIE) found that adding lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival (PFS) in pediatric and young adult patients with relapsed osteosarcoma.

Atezolizumab and nivolumab-based regimens failed to meet primary endpoints in improving disease-free survival (DFS) for resected renal cell carcinoma (RCC).

A phase 3 trial (ENGOT-en11/GOG-3053/KEYNOTE-B21) showed that adding pembrolizumab to adjuvant chemotherapy did not improve disease-free survival (DFS) in high-risk endometrial cancer patients.

A subgroup of patients with dMMR high-risk endometrial cancer showed improved disease-free survival (DFS) with adjuvant pembrolizumab plus chemotherapy.

Belzutifan maintained improved progression-free survival (PFS) and objective response rate (ORR) compared to everolimus in previously treated advanced clear cell RCC.